FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma-Reference-Cited by-同舟云学术

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Published:2021-05 Issue:5 Volume:32 Page:609-619
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sahin U.,Türeci Ö.,Manikhas G.,Lordick F.,Rusyn A.,Vynnychenko I.,Dudov A.,Bazin I.,Bondarenko I.,Melichar B.,Dhaene K.,Wiechen K.,Huber C.,Maurus D.,Arozullah A.,Park J.W.,Schuler M.,Al-Batran S.-E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference22 articles.

1. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

2. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group;Van Cutsem;J Clin Oncol,2006

3. Chemotherapy for advanced gastric cancer;Wagner;Cochrane Database Syst Rev,2017

4. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Smyth;Ann Oncol,2016

5. Progress in the treatment of advanced gastric cancer;Song;Tumor Biol,2017

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach;Modern Pathology;2024-11

2. Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy;Pathology - Research and Practice;2024-10

3. The Clinicopathological and Molecular Characteristics of Endocervical Gastric-Type Adenocarcinoma and the Use of Claudin18.2 as a Potential Therapeutic Target;Modern Pathology;2024-10

4. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

5. United Kingdom and Ireland Oesophagogastric Cancer Group Cancer Update 2023;Clinical Oncology;2024-09